There were 165 press releases posted in the last 24 hours and 397,557 in the last 365 days.

MJ Biotech Inc. Announces Joint Venture with THALGO USA.COM

CHEYENNE, Wyo., April 13, 2018 (GLOBE NEWSWIRE) -- MJ Biotech, Inc. (FKA Michael James Enterprises, Inc.) (OTC:MJTV) announced that it executed a Preferred Partner agreement with THALGO USA https://www.thalgousa.com located in South Florida under the dynamic leadership of THALGO USA CEO Christophe Justens of South Florida and France to expand the THALGO USA distribution footprint and enhance consumer awareness in the USA, as we share the share the same goals and mission for the promotion of a Holistic lifestyle, natural health and wellness.

THALGO was founded in France in 1964, and has become the premier name in the global world of “Marine Beauty."  Creating, manufacturing and marketing treatments, cosmetic products and marine-based nutritional supplements in more than 90 countries and in 20,000 + outlets across the world. Through its commitment to create Beauty through Innovation, Thalgo USA and its spa partners deliver immediate and measurable results for anyone looking to enhance their skin, from the outside and inside. We feel that the MJTV/Zen’s Tea House focus on holistic wellness is a perfect complement.

Headquartered in the Southeast of France, the THALGO Group has 450 employees, and is committed to research and innovation with its 2 laboratories and serves over 20,000 top spas, resorts and Thalassotherapy centers in more than 90 countries. The MJ BIOTECH / Zen’s Tea House holistic medicine/wellness and enthusiastic enhanced lifestyle commitment makes this relationship with THALGO USA very exciting indeed.

Subscribe to the Zen’s Tea House YouTube Channel: https://youtu.be/5Q14Fmr_u3k to see COO of MJ Biotech, Fernando Lopez, discuss company sales with Donald Baillargeon of MoneyTV. Additional information is available on the company’s websites, www.mjbiotech.us and www.zenstea.com 

Safe Harbor Statement: This release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are commonly identified by words such as "would," "may," "will," "expects," and other terms with similar meaning. Forward-looking statements are based on current beliefs, assumptions and expectations and speak only as of the date of this release and involve risks and uncertainties that could cause actual results to differ materially from current expectations. We assume no obligation to update or revise any forward-looking statement, whether because of new information, future events or any other reason.

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Contact: Fernando Lopez

Fernando@zenstea.com

Source: MJ Biotech, Inc.

Primary Logo

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.